Global Information
회사소개 | 문의

안구건조증 제품 보고서(2017년) : 세계 시장 분석(2016-2022년)

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022

리서치사 Market Scope, LLC
발행일 2017년 12월 상품 코드 644803
페이지 정보 영문
US $ 4,500 ₩ 5,140,800 Hard Copy
US $ 5,000 ₩ 5,712,000 Hard Copy & PDF by E-mail (Single User License)
US $ 6,750 ₩ 7,711,200 Hard Copy and PDF by E-mail (Enterprise License)

안구건조증 제품 보고서(2017년) : 세계 시장 분석(2016-2022년) 2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022
발행일 : 2017년 12월 페이지 정보 : 영문


세계의 안구건조증 치료제 시장은 2017년 37억 달러에 이르렀으며, 2022년에는 49억 달러에 달할 것으로 예측됩니다. 인구 고령화, 부의 확대, 의료 접근 개선 등에 의해 두 자리수대의 연간 성장률이 전망되는 중국, 인도, 기타 신흥 시장에서 가장 높은 성장률이 전망되고 있습니다.

안구건조증(Dry Eye)의 원인·진단·치료, 안구건조증의 유병률, 안구건조증용 처방약, OTC 인공누액, 누점 플러그, 기타 안구건조증 치료법 및 제품에 대해 조사했으며, 안구건조증 제품 제조업체·유통업체 개요 등의 정보를 전해드립니다.

1. 서론

2. 주요 요약

3. 안구건조증 개요

  • 정상적인 눈물의 기능
  • 안구건조증의 원인
  • 국제 안구건조증연구회(DEWS)의 안구건조증 분류
    • 눈물결핍
    • 비쇼그렌 증후군 눈물결핍
    • 쇼그렌 증후군 눈물결핍
    • 증발성 안구건조증
  • 염증의 역할
  • 호르몬과 안구건조증
  • 라식과 안구건조증
    • 눈꺼풀 앞쪽 안검염
    • 후방 안검염

4. 세계의 안구건조증 치료

  • 안과의
  • 검안의
  • 안구건조증 전문 치료센터

5. 안구건조증 기관

6. 안구건조증 진단

  • 증상 vs. 객관적 징후
  • 안구건조증 설문조사
  • 기존의 안구건조증 진단 방식
  • 새로운 안구건조증 진단 방식

7. 안구건조증 유병률

  • 안구건조증 증후군 유병률 추정
  • 세계의 안구건조증 환자수
  • 안구건조증 환자수 및 예비환자 : 국가/분류별
  • 안구건조증 중증
  • 치료 빈도
  • 치료 종료 vs. 미치료 안구건조증

8. 치료 및 제품 개요

  • 제품 및 시장 세분화

9. 안구건조증 처방약(Rx)

  • 항염증제
  • 코르티코스테로이드
  • 비스테로이드성 항염증제
  • 분비 촉진제
  • 점탄성 인공누액
  • 히알루론산나트륨 제네릭 제품
  • 항감염증제
  • 기타 작용기전의 약제
  • 전신 처방약

10. 처방약(Rx) 개발 파이프라인

  • 항염증제, 면역조절제
  • HA 인공누액 처방약
  • 분비 촉진제 및 기타 점액 강화제(Mucin Enhancers)
  • 기타 치료제
  • 쇼그렌 증후군 표적 의약품
  • US Phase III Recap
  • 약물 전달
  • 정지·중지된 안구건조증 후보의약품

11. 안구건조증 치료 제품

  • 누점 플러그
  • MGD용 치료법과 기기
  • 조직공학과 재생 등

12. OTC 윤활 점안 제품

  • 주요 인공누액 제품
  • 기타 인공누액 제품
  • 구조와 분류
  • 하이브리드 OTC/Rx 인공누액

13. 세계의 안구건조증 시장 예측

  • Rx(처방약) 시장 부문
  • 치료법 시장 부문
  • OTC 시장 부문

14. 기타 안구건조증 제품, 치료법

  • OTC 영양 강화
  • 기타 안구건조증 치료

15. 기업 개요

LSH 18.06.11


In this report, we examine dry eye syndrome's etiology, diagnosis, and treatment; the prevalence of dry eye; Rx therapeutics for dry eye; over-the-counter lubricants; punctum plugs; and additional dry eye procedures and products. The report also includes profiles of the companies that make and distribute dry eye products. Our analytic categories are the US, Western Europe, Japan, Other Wealthy Nations, China, India, Latin America, and Rest of World (a mix of developing nations and underdeveloped countries).

What's new: Market Scope expects the global dry eye treatments market to total $3.7 billion in 2017 and reach $4.9 billion in 2022. The highest rate of growth is expected to occur in China, India, and other emerging markets where we forecast double-digit annual growth rates due to aging populations, increasing wealth, and improving access to health care. In 2016, the US saw its first new pharmaceutical treatment in 13 years hit the ground running, with Shire's Xiidra (lifitegrast). Allergan, maker of Restasis, gained US clearance in 2017 for a new device, a neurostimulator, called TrueTear.



Kristen Ingenito

Kristen Ingenito has more than a decade of experience in the ophthalmic industry, with eight of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Kristen earned her bachelor's degree from the University of Missouri-St. Louis and is currently pursuing a Master of Business Administration at The George Washington University School of Business as a Forté Fellow.

In addition to her research and writing efforts on the ophthalmic market, she is a contributor to Ophthalmic Market Perspectives, the firm's monthly industry newsletter, and, a data portal for surgeons. When she's not crunching numbers or building charts, Kristen enjoys spending time outdoors with her husband, daughter, and rescue dog.

Our report is organized into key areas and includes:

  • Dry Eye Overview
  • Care for Dry Eye
  • Diagnosis of Dry Eye
  • Treatment Modalities for Dry Eye
  • Prevalence of Dry Eye
  • The Global Dry Eye Treatment Market
  • The Rx Product Market Segment
  • Recent Rx Development Pipeline
  • The Rx Product Market Segment
  • Over-the-counter Market Segment
  • Procedure Market Segment
  • Punctum Plug Market Segment
  • Dry Eye Procedures
  • Additional Dry Eye Products
  • Dry Eye Organizations

Table of Contents


  • Scope
  • Methodology
  • About the Author
  • The Report at a Glance


  • The Challenges of Dry Eye Disease
  • Dry Eye Products Market Segments
  • Market Competitors


  • Normal Tear Function
  • Causes of Dry Eye
  • DEWS Classification of Dry Eye
  • Tear Deficiency
  • Non-Sjögren's Tear Deficiency
  • Sjögren's Syndrome Tear Deficiency
  • Evaporative Dry Eye
  • The Role of Inflammation
  • Hormones and Dry Eye
  • LASIK and Dry Eye
  • Notes on Blepharitis
  • Anterior Blepharitis
  • Posterior Blepharitis


  • Ophthalmologists
  • Population per Ophthalmologist
  • Optometrists
  • Dedicated Dry Eye Treatment Centers


  • Sjögren's Syndrome Foundation
  • Tear Film and Ocular Surface Society
  • Cornea Research Foundation of America


  • Symptoms Versus Objective Signs
  • Dry Eye Questionnaires
  • Conventional Approaches to Dry Eye Diagnosis
  • Diagnostic Staining
  • Tear Break-up Time (TBUT)
  • Schirmer Test
  • Effectiveness of Conventional Dry Eye Tests
  • Clinical Examination
  • Newer Approaches to Dry Eye Diagnosis
  • TearLab Osmolarity System
  • J&J Vision (formerlyTearScience) LipiView Ocular Surface Interferometer
  • J&J Vision LipiScan Meibomiam Imaging
  • Oculus Keratograph 5M
  • RPS/Nicox InflammaDry Detector
  • Tomey Tear Stability Analysis System (TSAS)
  • Advanced Tear Diagnostics TearScan MicroAssay System
  • Bausch + Lomb (Valeant) Sjö Diagnostic Panel
  • Other New Approaches
  • DEWS on Dry Eye Diagnostics
  • The Dry Eye Diagnostic Market


  • Beaver Dam Eye Study
  • Salisbury, MD, Study
  • Extension Blue Mountains Eye Study
  • Melbourne Visual Impairment Project
  • The Canadian Dry Eye Epidemiology Study
  • Women, Menopause, Menopausal Hormone Therapy
  • Physician's Health Studies
  • Shanghai, China, Study
  • Additional Prevalence Studies
  • Estimating the Prevalence of Dry Eye Syndrome
  • Worldwide Dry Eye Populations
  • Dry Eye Populations and Contributors by Country/Category
  • United States' Dry Eye Contributors
  • Western Europe's Dry Eye Contributors
  • Japan's Dry Eye Contributors
  • Other Wealthy Nations' Dry Eye Contributors
  • China's Dry Eye Contributors
  • India's Dry Eye Contributors
  • Latin America's Dry Eye Contributors
  • Rest of World's Dry Eye Contributors
  • Dry Eye Severity
  • Treatment Frequency
  • Treated versus Untreated Dry Eye


  • Products and Market Segments


  • Anti-inflammatory Agents
  • Allergan: Restasis
  • Shire: Xiidra
  • Santen: Ikervis
  • Corticosteroids
  • Nonsteroidal Anti-inflammatories
  • Secretagogues
  • Santen: Diquas
  • Otsuka: Mucosta Ophthalmic
  • Viscoelastic Lubricants
  • Santen: Hyalein
  • TRB Chemedica: Vismed
  • Generic Sodium Hyaluronate Products
  • Anti-infective Agents
  • Agents with Other Mechanisms
  • Mitotech Russia: Vizomitin (SkQ1)
  • Sustained-Release Rx Therapeutics
  • Valeant Pharmaceuticals: Lacrisert
  • Systemic Rx Therapeutics
  • Daiichi Sankyo: Evoxac
  • Pilocarpine Agents: Salagen from Eisai and Others


  • Anti-inflammatories and Immunomodulators
  • Allergan: Restasis X
  • Sun Pharma: Seciera
  • DH Bio/BTO Pharm: Haporine-S
  • Han Lim Pharmaceutical: Tisporin
  • Kala Pharmaceuticals: INVELTYS (KPI-121)
  • Kissei Pharmaceutical: KCT-0809
  • Novaliq: CyclASol
  • RegeneRx/G-treeBNT/ReGenTree: RGN-259
  • HA Lubricating Rx Agents
  • Seikagaku: SI-614
  • Secretagogues and Other Mucin Enhancers
  • Dong-A ST: DA-6034
  • Mimetogen Pharmaceuticals: Tavilermide (MIM-D3)
  • Additional Therapeutic Candidates
  • Parion Sciences: P-321
  • Sylentis: SYL-1001
  • Winston Pharmaceuticals' Civamide Nasal Solution
  • Dompé: rhNGF Eye Drops
  • KT&G Life Sciences: KL7016
  • Laboratoires Théa: T2762
  • Mitotech: Vizomitin (SkQ1)
  • Targeting Sjögren's Syndrome
  • Novartis: VAY736
  • US Phase III Recap
  • Drug Delivery
  • InSite Vision: DuraSite 2 and ISV-101
  • Novaliq: CyclASol
  • Ocular Therapeutix: OTX-DP
  • Stalled or Abandoned Dry Eye Product Candidates


  • Punctum Plugs
  • Punctum Plug Applications
  • Punctum Plug Manufacturers
  • Cost of Punctum Plugs
  • Punctum Plug Development
  • Procedures and Devices for MGD
  • J&J Vision (formerly TearScience) LipiFlow Procedure
  • MiBoMedical Group MiBoFlo ThermoFlo Procedure
  • Intense Pulsed Light (IPL)
  • Gulden Ophthalmics MG Expressor Kit
  • Laboratoires Théa Blephasteam
  • Rhein Medical's Maskin Meibomian Gland Intraductal Probe
  • RySurg's BlephEx
  • Tissue Engineering and Regeneration
  • Bio-Tissue's ProKera
  • Katena/IOP Ophthalmics' Dehydrated Amniotic Membrane
  • Reservoir and Hydration-based Procedures and Devices
  • Boston Foundation for Sight's PROSE Treatment
  • Blanchard Contact Lenses Onefit
  • Alternative Technologies
  • Allergan's TrueTear Nueronasal Stimulator
  • Investigational Procedures and Devices
  • Lacrimal Abdominal Reservoir
  • Tear Film Innovations: iLux


  • Lubricating Drops
  • Ointments and Gels
  • Leading Artificial Tear Products
  • Alcon (Novartis): Systane
  • Allergan: Refresh and Optive
  • J&J Vision: Blink Tears
  • Bausch + Lomb: Soothe and Advanced Eye Relief
  • Akorn's TheraTears
  • Oasis Medical's Oasis Tears
  • Johnson & Johnson's Visine
  • Additional Artificial Tears Products
  • Novaliq: NovaTears
  • OCuSOFT's Retaine
  • OCuSOFT: Tears Again
  • Paragon BioTeck: EqualEyes
  • Santen/Novagali: Cationorm
  • Similasan: Dry Eye Relief
  • Spectrum Thea: Thealoz
  • New Developments
  • Composition and Classification
  • Chemical Composition of Lubricating Tears and Gels
  • Preservative Use in Lubricating Tears and Gels
  • Classification by Packaging
  • Hybrid OTC/Rx Lubricants
  • TRB Chemedica's Vismed
  • Allergan's Optava


  • Global Market for Dry Eye Products
  • Company Market Share
  • The Rx Market Segment
  • Forecast for the Rx Product Market Segment
  • Company Market Share in Rx Segment
  • The Procedure Market Segment
  • The Market in Newer Procedures
  • Forecast for the Punctum Plug Market Segment
  • OTC Market Segment
  • Forecast for the OTC Market Segment
  • Company Market Share in the OTC Segment


  • OTC Nutritional Supplementation
  • Studies
  • TRB Chemedica's Remogen Omega
  • ScienceBased Health's HydroEye SoftGels
  • BioSyntrx' BioTears Oral Gel Caps
  • Akorn's TheraTears Nutrition
  • Other Supplements
  • Other Dry Eye Treatments
  • Autologous Serum Eye Drops
  • Lateral Tarsorrhaphy
  • Moisture Shielding Eyewear


  • Company Share in the Dry Eye Market
  • Akorn, Inc.
  • Alcon, Inc.
  • Allergan plc
  • Bausch + Lomb
  • Beaver-Visitec International, Inc.
  • BioSyntrx, Inc.
  • Bio-Tissue, Inc.
  • Eagle Vision, Inc.
  • FCI Ophthalmics
  • Gulden Ophthalmics
  • Johnson & Johnson Vision
  • Kala Pharmaceuticals
  • Katena Products
  • Laboratoires Théa
  • Lacrimedics, Inc.
  • Medennium, Inc
  • Mimetogen Pharmaceuticals
  • Oasis Medical, Inc.
  • OCuSOFT, Inc.
  • Ocular Therapeutix
  • Otsuka Pharmaceutical Co., Ltd.
  • Rhein Medical, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • ScienceBased Health, Inc.
  • Senju Pharmaceutical Co., Ltd.
  • Shire Plc
  • Similasan
  • Sun Pharmaceutical Industries, Inc.
  • Surgical Specialties Corporation
  • Tear Film Innovations
  • TearLab Corporation
  • TRB Chemedica International S.A.



Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
BCC Research